Introduction
============

Cell-mediated immunity is considered critical for the prevention and control of many viral infections \[[@B1]-[@B6]\]. The approaches developed to detect these responses in vitro have evolved over the years and have provided quantitative and qualitative information on virus-specific T cells for a number of viral infections. These assays include, besides others, lymphoproliferative assays using ^3^H-thymidine incorporation or CFSE staining, limiting dilution precursor-frequency assays for the enumeration of CTL precursor frequencies, intracellular cytokine staining (ICS) and enzyme-linked immunospot (ELISpot) assays \[[@B7]-[@B10]\]. Although these assays differ in their minimal cell requirements, the detailed, simultaneous analysis of anti-viral immunity against multiple viral infections is often limited by cell availability, regardless of the assay employed.

The ELISpot assay has become widely used for rapidly assessing cellular immune responses to extensive numbers of antigens while using relatively few cells. A number of studies have also employed peptide matrix approaches, where every antigenic peptide is tested in two peptide pools, so that responses to reactive pools sharing a specific peptide can help to identify the targeted peptide \[[@B9],[@B11]\]. This has reduced the required cell numbers significantly, so that for instance HIV-specific responses can generally be comprehensively assessed using less than 15 × l0^6^cells \[[@B9]\]. However, despite such advances, the simultaneous enumeration of virus-specific immunity to multiple viral infections still exceeds the required sample size that can routinely be obtained. Sample size may not be of great concern when assessing CTL mediated immune responses against single, small genome viruses such as HIV and HCV, which can be tested in a comprehensive manner using overlapping peptide sets spanning the entire expressed viral genome \[[@B9],[@B12]\]. Nevertheless, such comprehensive approaches are not feasible for larger viruses, such as DNA-based herpesviruses like EBV, CMV and KSHV \[[@B4],[@B13]\]. Instead, immune analyses need either to be restricted to a selected number of specific viral proteins, or to the use of previously defined, optimal CTL epitopes. Responses against such optimally defined epitopes can account for a significant part of the total virus-specific immune responses, especially when they represent immunodominant epitopes covering the most immunogenic proteins of specific viral genomes. For well-studied viruses such as HIV, HCV, EBV and CMV, large sets of such optimally defined CTL epitopes, restricted by common HLA alleles, have been described in the past \[[@B14]-[@B17]\], and provide a valuable alternative to measure pathogen-specific CTL responses without the need to synthesize comprehensive peptide sets spanning the entire viral genomes.

The present study describes an algorithm by which matrices of optimally defined CTL epitopes derived from five different human viral infections are used in the same ELISpot assay. As not all wells of the ELISpot plate contain antigens to which the tested PBMCs will respond, there are consistently some wells with cells that have not been stimulated during this first assay. Theoretically, these cells could be recovered from the ELISpot plate before developing it and re-used in subsequent analyses. Indeed, others have suggested the use of \"recycled\" cells for DNA isolation\[[@B18]\], however, to our knowledge, no data exist on re-using these cells in functional assays. Since the peptide matrix approach is ideally followed by the subsequent confirmation of single targeted peptides present in two corresponding peptide pools, recycled cells from unstimulated ELISpot wells could be used for these assays. Although this second step could be achieved using in vitro expanded cells, for instance by anti-CD3 monoclonal antibody (mAb) stimulation, expanded cells may lose some of the responses compared directly to cells tested ex vivo \[[@B19],[@B20]\]. In addition, the absolute and relative magnitude of responses may be distorted during cell expansion and assays can only be run after prolonged in vitro culture\[[@B21],[@B22]\] Therefore, as long as functionality of recycled cells in secondary assays can be ensured, they may provide a simple way to complete initial ELISpot screenings, yielding reliable information on the magnitude of specific CTL responses. The feasibility of this approach was tested and it was shown that combined use of optimal epitope matrices, in vitro T cell expansion and RecycleSpot can provide relevant immune data on multiple viral infections even when cell availability is severely limited.

Materials and methods
=====================

Isolation of fresh PMBCs from whole blood
-----------------------------------------

Whole blood was collected using Citrate Vacutainer tubes (BD, Franklin Lakes, NJ) and peripheral blood mononuclear cells (PBMC) were isolated by Histopaque (Histopaque^®^1077, Sigma, St. Louis, MO) density centrifugation as described \[[@B9]\]. Fresh PBMC were either used directly after isolation, after in vitro expansion or after freezing and thawing with and without subsequent in vitro expansion. For in vitro use, cells were re-suspended in R10 medium (RPMI 1640 containg 10% heat inactivated FCS (both Sigma), 2 mM L-glutamine, 50 U/ml penicillin, 50 μg/ml streptomucin and 10 mM HEPES (all Mediatech, Hemdon, VA)) at a concentration of 1 × 10^6^cells/ml. Cells were thawed using R10 medium containing 50 U/ml DNAse (Deoxyribnuclease I, RNase-free, Sigma), washed twice in the same medium, re-suspended in R10 and incubated at 37°C with 5% CO~2~for 3--4 hours before they were counted and re-suspended in R10 at 1 × 10^6^cells/ml. The thawed cells were then either used directly in ELISpot assays or expanded.

For in vitro expansion, 1 to 5 × 10^6^PBMC were added to 25 ml culture flasks in 10 ml R10 supplemented with 1 μl of the anti-CD3 specific monoclonal antibody (mAb) 12F6 \[[@B23]\]. Cells were fed twice a week using R10 supplemented with 50 U/ml of recombinant Interleukin 2 (IL-2) for 2 weeks. Before use in ELISpot assays, cells were washed twice in R10 medium and incubated overnight at 37°C with 5% CO~2~in the absence of IL-2. This overnight starving step was necessary to eliminate background in the subseqnet ELISpot assay, which was, in our hands, not an issue, regardless of how long the *in vitro*culture had been maintained.

Design of Optimal Peptide Matrix
--------------------------------

A total of 416 optimal epitopes from five different viruses were assembled in 98 different peptide pools and used in 5 peptide matrices each containing peptides from a single virus. The number of pools and total number of peptides contained in each virus-specific peptide matrix are summarized in Table [1](#T1){ref-type="table"}. Each peptide was present at a final concentration of 200 μg/ml in the peptide pools. Detailed lists of all optimal epitopes included in this study, along with their sequence and HLA restriction, are given in Tables [2](#T2){ref-type="table"} through [6](#T6){ref-type="table"}.

###### 

Virus specific peptide matrix design using previously defined HLA class I restricted CTL epitopes

  **Virus**   **Optimal epitopes**   **No. of peptide pools**   **Max. no. of peptides per pools**
  ----------- ---------------------- -------------------------- ------------------------------------
  **HIV**     173                    29                         14
  **EBV**     91                     23                         12
  **CMV**     38                     13                         7
  **HCV**     77                     19                         11
  **HBV**     37                     14                         8

###### 

Optimal HIV-derived HLA class I restricted CTL epitopes

  Protein     HLA Restriction   Sequence       Position
  ----------- ----------------- -------------- ----------
  gp120       A02               RGPGRAFVTI     311--320
  gp120       A03               TVYYGVPVWK     37--46
  gp120       A11l              SVITQACPK      199--207
  gp120       A24               LFCASDAKAY     53--62
  gp120       A29               SFEPIPIHY      209--217
  gp120       A30               HIGPGRAFY      310--318
  gp120       A32               RIKQIINMW      419--427
  gp120       B07               RPNNNTRKSI     303--312
  gp120       B08               RVKEKYQHL      2--10
  gp120       B1516/Cw04        SFNCGGEFF      379--387
  gp120       B3801             MHEDIISLW      104--112
  gp120       B35               VPVWKEATTTL    42--52
  gp120       B35               DPNPQEVVL      77--85
  gp120       B44               AENLWVTVY      30--38
  gp120       B51               LPCRIKQII      416--424
  gp120       B55               VPVWKEATTT     42--51
  gp120       A33               VFAVLSIVNR     187--196
  gp120       A33               EVAQRAYR       320--327
  gp41        A01               RRGWEVLKY      787--795
  gp41        A02               SLLNATDIAV     818--827
  gp41        A0205             RIRQGLERA      335--343
  gp41        A03/A30           RLRDLLLIVTR    775--785
  gp41        A23/A24           RYLKDQQLL      591--598
  gp41        A30               IVNRNRQGY      704--712
  gp41        A30               KYCWNLLQY      794--802
  gp41        A6802             IVTRIVELL      782--790
  gp41        B07               IPRRIRQGL      843--851
  gp41        B08               YLKDQQLL       591--598
  gp41        B08               RQGLERALL      848--856
  gp41        B14               ERYLKDQQL      589--597
  gp41        B2705             GRRGWEALKY     791--799
  gp41        B35               TAVPWNASW      611--619
  gp41        B4001             QELKNSAVSL     810--819
  gp41        Cw3/Cw15          RAIEAQQHL      46--54
  p17         A02               SLYNTVATL      77--85
  p17         A03               KIRLRPGGK      18--26
  p17         A03               RLRPGGKKK      20--28
  p17         A03               RLRPGGKKKY     20--29
  p17         A11               TLYCVHQRI      84--92
  p17         A24               KYKLKHIVW      28--36
  p17         A30               RSLYNTVATLY    74--86
  p17         B08               GGKKKYKL       24--31
  p17         B08               ELRSLYNTV      74--82
  p17         B2705             IRLRPGGKK      19--27
  p17         B35               WASRELERF      36--44
  p17         B35               NSSKVSQNY      124--132
  p17         B4001             IEIKDTKEAL     92--101
  p17         B4002             GELDRWEKI      11--19
  p24         A0207             YVDRFYKTL      164--172
  p24         A11               ACQGVGGPGHK    349--359
  p24         A24/B44           RDYVDRFFKTL    296--306
  p24         A25               QAISPRTLNAW    145--155
  p24         B07               SPRTLNAWV      148--156
  p24         B07/B42/B81/Cw8   TPQDLNTML      48--56
  p24         B07               GPGHKARVL      223--231
  p24         B07               HPVHAGPIA      84--92
  p24         B08               EIYKRWII       260--267
  p24         B08               DCKTILKAL      329--337
  p24         B14               DRFYKTLRA      298--306
  p24         B1501             GLNKIVRMY      267--277
  p24         B18               FRDYVDRFYK     293--302
  p24         B2703             RRWIQLGLQK     260--269
  p24         B2705             KRWIILGLNK     265--274
  p24         B35               NPVPVGNIY      245--253
  p24         B35               PPIPVGDIY      254--262
  p24         B39               GHQAAMQML      193--201
  p24         B4001             SEGATPQDL      176--184
  p24         B4002             KETINEEAA      70--78
  p24         B4002             AEWDRVHPV      78--86
  p24         B44               AEQASQDVKNW    174--184
  p24         B44               EEKAFSPEV      28--36
  p24         B52               RMYSPTSI       143--150
  p24         B53               TPYDINQML      48--56
  p24         B53/B57           QASQEVKNW      176--184
  p24         B57               ISPRTLNAW      15--23
  p24         B57               KAFSPEVIPMF    30--40
  p24         B57               TSTLQEQIGW     108--118
  p24         B57               KAFSPEVI       30--37
  p24         B58               TSTLQEQIGW     108--117
  p24         B58               TSTVEEQIQW     108--117
  p24         Cw0I              VIPMFSAL       36--43
  p24         A25               ETINEEAAEW     71--80
  p24         A26               EVIPMFSAL      35--43
  p15         A02               FLGKIWPSYK     1--10
  p15         B14               CRAPRKKGC      42--50
  p15         B4001             KELYPLTSL      33--41
  p15         B4002             TERQANFL       64--71
  Protease    A6802/A74         ITLWQRPLV      3--11
  Protease    A6802             DTVLEEMNL      30--38
  Integrase   A30               KIQNFRVYY      219--227
  Integrase   A03/A11           AVFIHNFKRK     179--188
  Integrase   B1503             RKAKIIRDY      263--271
  Integrase   B42               VPRRKAKII      260--268
  Integrase   B57               KTAVQMAVF      173--181
  RT          A26               ETKLGKAGY      604--612
  RT          A02               ALVEICTEM      33--41
  RT          A02               VIYQYMDDL      179--187
  RT          A02               ILKEPVHGV      309--317
  RT          A03               ALVEICTEMEK    33--43
  RT          A03               GIPHPAGLK      93--101
  RT          A03/A1 1          AIFQSSMTK      158--166
  RT          A03               QIYPGIKVR      269--277
  RT          A03               KLVDFRELNK     73--82
  RT          A03               RMRGAHTNDVK    356--366
  RT          A11               IYQEPFKNLK     341--350
  RT          A11               QIIEQLIKK      80--88
  RT          B51               TAFTIPSI       128--135
  RT          B57               IVLPEKDSW      244--252
  RT          B58               IAMESIVIW      375--383
  RT          B81               LFLDGIDKA      715--723
  RT          B1503             VTDSQYALGI     651--660
  RT          A30               KQNPDIVIY      173--181
  RT          A30               KLNWASQIY      263--271
  RT          A30               RMRGAHTNDV     356--365
  RT          A32               PIQKETWETW     392--401
  RT          B08               GPKVKQWPL      18--26
  RT          B1501             LVGKLNWASQIY   260--271
  RT          B1501             IKLEPVHGVY     309--318
  RT          B35               TVLDVGDAY      107--115
  RT          B35               VPLDEDFRKY     118--127
  RT          B35               NPDIVIYQY      175--183
  RT          B35               HPDIVIYQY      175--183
  RT          B4001             IEELRQHLL      202--210
  RT          B42               YPGIKVRQL      271--279
  RT          B51               EKEGKISKI      42--50
  Vpr         A02               AIIRILQQL      59--67
  Vpr         B07/B81           FPRIWLHGL      34--42
  Vpr         B51               EAVRHFPRI      29--37
  Vpr         B57               AVRHFPRIW      30--38
  Tat         A6801             ITKGLGISYGR    39--49
  Tat         B1503             FQTKGLGISY     38--47
  Tat         B53               EPVDPRLEPW     2--11
  Tat         Cw12              CCFHCQVC       30--37
  Vif         A03               RIRTWKSLVK     17--26
  Vif         A03               HMYISKKAK      28--36
  Vif         A03               KTKPPLPSVKK    158--168
  Vif         B07               HPRVSSEVHI     48--57
  Vif         B18               LADQLIHLHY     102--111
  Vif         B57               ISKKAKGWF      31--39
  Nef         A02               PLTFGWCYKL     136--145
  Nef         A02               VLEWRFDSRL     180--189
  Nef         A03/A11           QVPLRPMTYK     73--82
  Nef         A03/A11           AVDLSHFLK      84--92
  Nef         A11               PLRPMTYK       75--82
  Nef         A24               RYPLTFGW       134--141
  Nef         A33               TRYPLTFGW      133--141
  Nef         B07               FPVTPQVPLR     68--77
  Nef         B07               FPVTPQVPL      68--76
  Nef         B07               TPQVPLRPM      71--79
  Nef         B07               RPMTYKAAL      77--85
  Nef         B07               TPGPGVRYPL     128--137
  Nef         B07               RQDILDLWIY     106--115
  Nef         B08               WPTVRERM       13--20
  Nef         B08               FLKEKGGL       90--97
  Nef         B1501             TQGYFPDWQNY    117--127
  Nef         B1501             RMRRAEPAA      19--27
  Nef         B1503             WRFDSRLAF      183--191
  Nef         B18/B53           YPLTFGWCY      135--143
  Nef         B2705             RRQDILDLWI     105--114
  Nef         B35               VPLRPMTY       74--81
  Nef         A01/A29/837/857   YFPDWQNYT      120--128
  Nef         B40               KEKGGLEGL      92--100
  Nef         B42               TPGPGVRYPL     128--137
  Nef         B53               YPLTFGWCF      135--143
  Nef         B57               HTQGYFPDWQ     116--125
  Nef         B57               HTQGYFPDW      116--124
  Nef         Cw07              RRQDILDLWIY    105--115
  Nef         Cw7               KRQEILDLWVY    105--115
  Nef         Cw8               AAVDLSHFL      83--91
  Rev         A03               ERILSTYLGR     57--66
  Rev         B57/B58           KAVRLIKFLY     14--23
  Rev         Cw05              SAEPVPLQL      67--75
  Vpu         A33               EYRKILRQR      29--37

All epitopes were referred from the Los Alamos HIV Immunology Database 2004 \[24\].

###### 

Optimal HBV-derived HLA class I restricted CTL epitopes

  Protein     HLA Restriction   Sequence      Position   Reference
  ----------- ----------------- ------------- ---------- ------------
  Core        A2                FLPSDFFPSV    18--27     \[84\]
  Core        A2                CLTFGRETV     107--115   \[85\]
  Core        A2                VLEYLVSFGV    115--124   \[85\]
  Core        A2/A24            EYLVSFGVW     117--125   \[86, 87\]
  Core        A2                ILSTLPETTV    139--148   \[86\]
  Core        A33/A68           STLPETTVVRR   141--151   \[88\]
  Core        A2                AILSKTGDPV    152--161   \[89\]
  Env         A2                LLDPRVRGL     131--139   \[85\]
  Env         A2                VLQAGFFLL     177--185   \[90\]
  Env         A2                FLLTRILTI     183--191   \[91\]
  Env         A2                SLNFLGGTTV    201--210   \[92\]
  Env         A2                FLGGTPVCL     204--212   \[89\]
  Env         A2                LLLCLIFLL     250--258   \[86\]
  Env         A2                LLCLIFLLV     251--259   \[92\]
  Env         A2                LLDYQGMLPV    260--269   \[92\]
  Env         A2                LVLLDYQGML    269--278   \[85\]
  Env         A2                VLLDYQGML     270--278   \[85\]
  Env         A2                LLDYQGMLPV    271--280   \[85\]
  Env         A2                WLSLLVPFV     335--343   \[92\]
  Env         A2                LLVPFVQWFV    338--347   \[92\]
  Env         A2                GLSPTVWLSV    348--357   \[92\]
  Env         A2                SIVSPFIPLL    370--379   \[89\]
  Env         A2                LLPIFFCLWV    378--387   \[92\]
  Env         A2                ILSPFFFLPLL   382--390   \[85\]
  x-Protein   A2                VLCLRPVGA     15--23     \[93\]
  x-Protein   A2                TLPSPSSSA     36--44     \[93\]
  x-Protein   A2                HLSLRGLFV     52--60     \[93\]
  x-Protein   A2                VLHKRTLGL     92--100    \[93\]
  x-Protein   A2                AMSTTDLEA     102--110   \[93\]
  x-Protein   A2                CLFKDWEEL     115--123   \[93\]
  Pol         A24               LYSSTVPVF     62--70     \[90\]
  Pol         A2                GLSRYVARL     455--463   \[90\]
  Pol         A2                YMDDVVLGA     551--559   \[91\]
  Pol         A2                FLLSLGIHL     575--583   \[90\]
  Pol         A24               KYTSFPWLL     756--764   \[87\]
  Pol         A2                ILRGTSFVYV    773--782   \[91\]
  Pol         A2                SLYADSPSV     816--824   \[91\]

ELISpot assay
-------------

96-well polyvinylidene plates (Millipore, Bedford, MA), pre-coated overnight with 2 μg/ml of anti-interferon gamma (IFN-γ) mAb 1-D1K (Mabtech, Stockholm, Sweden), were washed six times with sterile phosphate buffered saline (DPBS, no Ca & Mg, Mediatech) containing 1% fetal calf serum (FCS) before use. After washing, 30 μl of R10 were added to each well to avoid drying of the membrane, and 100,000 to 200,00 cells per well were added in 100 μl R10. 100,00 cells/well were used to detect responses to HIV, CMV and EBV, whereas responses to HCV and HBV were tested using 200,000 cells/well. Each peptide was added at a final concentration of 14 μg/ml (both single peptides as well as pools). As a negative control, cells were incubated in medium alone, and PHA was added at a concentration of 1.8 μg/ml to serve as a positive control. Plates were incubated for 16 h at 37°C with 5% CO~2~before being developed. After washing six times with PBS, 100 μl of biotinylated anti-IFN-γ mAB 7-B6-1 (0.5 μg/ml, Mabtech) were added and plates were incubated for 1 hour at room temperature (RT). The plates were washed again and incubated with a 1:2000 dilution of streptavidin-coupled alkaline phosphatase (Streptavidin-ALP-PQ Mabtech) for 1 hour at RT in the dark. After washing the plates again, IFN-γ production was detected as dark spots after a short incubation of 10--20 minutes with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (BioRad, Hercules, CA). The color reaction was stopped by washing plates with tap water and the plates were air-dried before counting using a AID ELISPOT Reader Unit (Autoimmun Diagnostika GmbH, Strassberg, Germany). Results were expressed as spot forming cells (SFC) per million input cells. Thresholds for positive responses were determined as either 5 spots (50 SFC/10^6^input cells) or as the mean plus 3 standard deviations of negative control wells, whichever was higher.

RecycleSpot
-----------

After overnight incubation in a primary ELISpot assay, cells from all wells of the ELISpot plate were transferred to a 96-well round-bottom plate and incubated at 37°C with 5% CO2 while developing the ELISpot assay. Cells from wells without any spots (including negative control wells) were then pooled, counted and used for secondary ELISpot assays. In control experiments, cells corresponding to wells with positive responses were also pooled, washed extensively (\>5 times) and re-used in subsequent, secondary ELISpot assays as well. Cells from positive control wells (PHA stimulated) were not used for subsequent assays.

Results
=======

Design of the optimal epitope matrix for five viral infections
--------------------------------------------------------------

To simultaneously test CTL responses against five different viruses with a limited number of PBMCs, a peptide matrix approach was used that included all previously published, well-defined CTL epitopes in HIV, HCV, HBV, EBV and CMV. The total number of described CTL epitopes for these viruses varied from 37 described optimal epitopes in HBV to more than 170 optimal epitopes in HIV. A list of all the optimal epitopes included in the present study is given in Tables [2](#T2){ref-type="table"} through [6](#T6){ref-type="table"}, totaling 416 well-defined, HLA class I-restricted CTL epitopes. The included HIV epitopes were derived from the annually updated list of HIV CTL epitopes at the Los Alamos National Laboratory HIV immunology database\[[@B24]\]. For all the other pathogens, the epitopes listed were those for which, to the best of our knowledge, at least one publication existed showing CTL activity against this epitope in at least one infected individual. While the optimal epitopes in HIV, HCV and HBV cover large parts of their respective viral genomes, the epitopes defined in EBV and CMV represent only a portion of the proteins expressed by these viruses. Given the approximately 100 open reading frames in these large-genome viruses, complete representation of all viral proteins can hardly be achieved and most studies on these pathogens have thus focused on a relatively small number of viral proteins, especially concentrating on those containing serological determinants and those characterized by specific viral gene expression patterns. Thus, described EBV and CMV encoded CTL epitopes are derived from eleven and four different viral proteins respectively, whereas the known HIV, HCV and HBV epitopes cover all the viral proteins in these small-genome pathogens.

As the number of described optimal CTL epitopes varies between pathogens, separate peptide matrices were designed for each virus (Table [1](#T1){ref-type="table"}). Importantly, the first set of pools (\"protein pools\") was designed so that the pools contained all the epitopes derived from the same viral protein, whereas the second half of matrix peptide pools contained the epitopes in a non-protein specific composition (\"random pools\"). This matrix design allowed assessment of the virus specific immune response at different levels of resolution including i) a \"total virus\" specific response by adding up all the protein pool specific or random peptide pool specific responses, ii) a \"protein\" specific responses by focusing on single pools containing all the epitopes of a given protein; and iii) upon single peptide confirmation, on a single epitope level, by comparing responses in pools containing the same epitope. Together, the epitope matrix design facilitated the assessment of T cell responses to more than 400 CTL epitopes from five different viruses simultaneously, using less than 10 × 10^6^PBMCs while still allowing determination of breadth and magnitude of virus-, protein-, and epitope-specific responses for each virus separately.

Moreover, since each epitope is tested twice in different pools, it should reflect the same magnitude of response in each pool, thus the matrix approach provides its own internal control. Additionally, \"protein pools\" and \"random pools\" should theoretically yield the same total magnitude of responses since they, as a whole, contain the same set of peptides. To test this, and rule out the possibility that peptide compositions in the different pools interfered with the detection of specific responses, the magnitude of all \"protein pool\" and \"random pool\" specific responses were compared in 19 subjects infected with EBV (n = 19) and co-infected with CMV (n = 14), HIV (12), and HCV (9). These analyses showed a statistically highly significant correlation between total magnitudes of responses detected by either set of peptide pools, indicating that the peptide mixtures in the pools sharing a specific response did not significantly impact the detection of the targeted epitope (Figure [1](#F1){ref-type="fig"}). Of note, for all four viruses analyzed, the \"random pools\" detected a slightly higher, statistically not significant total virus-specific response than the \"protein pools\". This is likely due to the presence of highly reactive epitopes which, when tested in the same peptide pool, can exceed the upper detection limit of the ELISpot assay and may thus underestimate the total virus-specific magnitude of responses. This may be more likely for epitopes in \"peptide pools\" than \"random pools\" if some proteins elicit generally stronger immune responses than others. A protein pool accumulating strongly reactive epitopes would result in fewer spots than the total of the respective \"random pools\" containing these epitopes equally distributed and fully quantitative.

![**Comparable magnitude of responses detected by \"protein\" and \"random\" peptide pools:**The magnitude of CTL responses was determined by adding magnitudes for all \"protein\" or \"random\" pools for each virus. Responses on the Y-axes represent the total of all virus specific \"random pools\", the X-axes indicate total responses detected using the \"protein pools\". Data from 12 HIV-, 19 EBV-, 14 CMV-, 9 HCV-infected individuals were tested against either set of peptide pools for A) HIV, B) HCV, C) EB V, and D) CMV and compared using the non-parametric Wilcoxon matched pairs test.](1479-5876-3-20-1){#F1}

Cells from negative ELISpot wells can be used in secondary ELISpot assays (RecycleSpot)
---------------------------------------------------------------------------------------

In order to maximize cell use in samples with limited cell availability, we investigated whether cells from initial ELISpot matrix screens could be re-used in subsequent functional assays. Specifically, cells from wells that did not respond to peptides added in the first assay as well as the cells in the negative control wells may be used for secondary ELISpot assays. To assess the feasibility of this strategy, all wells from the initial ELISpot plate were transferred to a 96-well plate and incubated at 37°C with 5% CO~2~while the ELISpot plate was developed. Cells from negative ELISpot wells were then used to confirm the identity of the epitope(s) targeted in the matrix peptide pools. In separate experiments, cells from initially positive wells were also tested in subsequent assays to determine if continuing IFN-γ production in these cells would prevent them from being used in further ELISpot assays. The analyses also compared ELISpot results in plates that were either undisturbed, or from which cells were transferred for later use.

Representative RecyleSpot assays using PBMC and recovered cells from initial ELISpot assays from three individuals are shown in Figure [2](#F2){ref-type="fig"}. In all cases, negative wells from initial peptide matrix ELISpot assays were re-used to reconfirm the identity of the presumed, single targeted epitope shared by the two pools. Further, initially positive pools were re-tested to assess whether recycled cells responded with a different magnitude compared to the initial assay. The data show that sufficient cells were recovered from initial assays to perform reconfirmations of single targeted epitopes in the RecycleSpot, and that background activity and magnitude of responses were not significantly different between the first and the subsequent assays. RecycleSpot assays that used initially positive wells, or mixtures of initially positive and negative wells, showed high background in the secondary assay, indicating ongoing IFN-γ production and thus precluding these cells from use in the RecycleSpot (data not shown). No effects on the quality and the number of spots between the manipulated and non-manipulated wells were observed, indicating that harvesting cells from the ELISpot plate did not negatively interfere with the quality of the assay, at least when cells are removed by careful pipetting using a 12-channel pipetor Furthermore, RecycleSpot assays were performed using both fresh and frozen/thawed cells and showed that HIV-and EBV-specific responses were maintained in recycled cells in both cases (data not shown). Together, the data indicate that RecycleSpot can provide sufficient numbers of cells from initial assays and that these cells maintain functional capacity for use in subsequent assays, without raising background activity. Also, the data show that re-using the cells form negative wells after an overnight incubation did not reduce the magnitude of responses to a statistically significant level.

![**RecycleSpot using recycled cells for the de-convolution of positive peptide pools:**Wells of primary ELISpot and secondary RecycleSpot are shown. Line A shows the data from the initial ELISpot assay, including two positive wells indicating cellular response to EBV peptide pools, three negative and one positive control wells. Line B shows the same outline as in A, this time with recycled cells in a secondary ELISpot analysis and, one separate well, using the predicted targeted epitopes from the matrix analysis. The numbers indicate the spot forming cells per million PBMC.](1479-5876-3-20-2){#F2}

In vitro expanded T cells mount responses detected in fresh ex vivo PBMC samples
--------------------------------------------------------------------------------

Even though rational optimal epitope matrix design and RecycleSpots may help in reducing the required cell numbers for in vitro analyses, cell availability may still be limiting in settings where only very small biological samples can be obtained. In such instances, investigators have resorted to the use of in vitro expanded cells \[[@B19],[@B20],[@B25]\]. However, despite its potential usefulness in situations of small sample size (e.g. tissue biopsies or small volume peripheral blood samples), relatively little is known on how in vitro expansion impacts magnitude and breadth of detectable responses \[[@B20],[@B25]\]. Furthermore, CTL responses to pathogens like HIV, for which a defect in their proliferative capacity has been shown, may be severely distorted by in vitro expansion, even when stimulated unspecifically \[[@B7]\]. To address this issue and to investigate whether stimulation of PBMC with an anti-CD3 mAb (12F6) expands CTL of different specificity equally well, we tested cells either directly or after expansion against peptide sets of described HIV- and EBV-specific epitopes restricted by the individual\'s HLA alleles.

These analyses included twelve subjects, of which seven were tested for responses to HIV and EBV epitopes, while the remaining five were tested for EBV-specific responses only (Figure [3](#F3){ref-type="fig"}).

![**In vitro expansion of thawed cells increases the magnitude and breadth of HIV and EBV specific responses:**Thawed PBMC from 12 individuals were tested against HIV and EBV peptide pools (n = 7 subjects) or against EBV peptide pools only (n = 5). Cells were used either directly after thawing or after thawing and a subsequent two-week in vitro expansion using the anti-CD3 mAb 12F6. A) The breadth of the detected responses (number of peptide pools reacting) and B) the total magnitude (sum of all positive peptide pools) is compared between the two cell preparation using the non-parametric Wilcoxon matched pairs test. C) PBMC from 5 EBV infected individuals were used either directly after isolation of after a two-week in vitro expansion or as frozen/thawed cells with and without in vitro expansion, and compared for the breadth (number of pools recognized) and D) total magnitude of the EBV specific responses.](1479-5876-3-20-3){#F3}

In a first analysis, frozen PBMC were either tested directly or after a 2-week stimulation using 12F6 and the number of targeted HIV or EBV epitopes were compared, resulting in 19 data points (seven individuals tested for HIV and EBV responses and five subjects tested for EBV-specific responses). Flow cytometry in nine individuals showed preferential expansion of CD8 T cells, as CD4 expressing T cells ranged between 0.5% and 14% only, independent of HIV infection and starting CD4 T cell counts (data not shown). The Elispot results revealed no difference in the breadth of responses (number of targeted epitopes) between the directly tested and the expanded cells, as a median of 6.4 and 6.9 positive responses were detected for HIV and EBV, respectively (Figure [3A](#F3){ref-type="fig"}). The recognition of HIV- and EBV-derived epitopes was equally frequent by the two different cell preparations (data not shown). When the magnitude of responses was compared between directly used and expanded cells, expanded cells responded with a slightly higher magnitude than unexpanded cells. This trend was more prominent when HIV and EBV responses were analyzed separately. The HIV responses in directly tested cells showed a median of 185 SFC/10^6^PBMC, as compared to 285 SFC/10^6^PBMC in expanded cells (p = 0.0005); whereas the median EBV-specific responses had a magnitude of 170 SFC/10^6^in unexpanded PBMC compared to 190 SFC/10^6^PBMC in expanded cells (p \> NS).

Moreover, to determine whether freshly isolated cells could also be expanded without drastic changes in their response patterns, PBMC from five EBV-infected subjects were tested directly after isolation, or after freezing, and with or without in vitro expansion. In agreement with the data from frozen samples, no significant difference in the number of pools targeted or the median magnitude of these responses was observed (Figure [3 C](#F3){ref-type="fig"} and [3 D](#F3){ref-type="fig"}). Despite concordance among the response patterns between the different cell preparations that was as low as 80%, the overall breadth and magnitude of these responses did not change. In addition, when comparing the magnitudes of the responses between each other, the relative magnitude of the responses was maintained between the four different cell preparations (data not shown). Combined, the data demonstrate that anti-CD3 expanded cells maintain their specificity and relative magnitudes when compared to unexpanded cells (both when used fresh or after thawing) indicating that in vitro expansion could be employed when the breadth, but not the absolute magnitude of responses, is being assessed. This was the case for the assessment of HIV- as well as the EBV-specific responses, suggesting that cells specific for HIV do not significantly differ from EBV specific cells in their ability to undergo in vitro expansion using a non-antigenic stimulus.

Discussion
==========

Cell availability can severely hamper in vitro analyses of antigen specific immune responses, hence approaches which optimize cell use are urgently needed. This is especially true for assays requiring extensive sets of antigens to be tested while only a limited number of cells can be obtained. However, logistic considerations may prevent repetitive sample collection for larger trials, and re-use of fresh or frozen samples could provide more effective ways to perform necessary analyses. The present study introduces a novel approach by which some of the sample limitations can be overcome, and may prove helpful in routine laboratory tests that currently do not make optimal use of available cells. This may not only facilitate currently performed assays, but may open possibilities to expand analyses to simultaneous assessment of even larger sets of antigens and additional functional aspects.

In the present study, we have designed and tested an approach that allows the assessment of the CTL mediated immunity against five different viral infections, including HIV, HCV, HBV, EBV and CMV. We provide an up-to-date listing of currently determined viral epitopes for which the minimal length and HLA restriction have been established. In the case of the small genome viruses HIV and HCV, these optimal epitopes represent a large portion of the respective immune targets \[[@B26]\]. Although they do not include all responses detected in OLP screenings, our comparative analyses of HIV-specific responses from 100 individuals detected by either overlapping peptide (OLP) sets or optimal epitopes show that on average 68% of the observed OLP responses are covered by previously established HIV optimal epitopes (data not shown).

The present data also show that PBMC recycled from negative wells from an ELISpot assay can be re-used for subsequent functional assays. Depending on the analyses performed in the subsequent assay, such as reconfirmation of single epitope responses predicted in the initial matrix analyses, relatively small numbers of cells maybe required. Thus, although individuals with broad responses in the initial ELISpot assay will not yield many negative wells from which to recycle cells, the wells with non-targeted peptide in addition to the negative control wells often provide sufficient quantities of recycled cells to complete the matrix based analyses. Since the responses in the RecycleSpot are not significantly diminished as compared to the initial assay (Figure [2](#F2){ref-type="fig"}), the magnitude of responses in the subsequent assay can still provide adequate data at the single epitope level.

In vitro expanded cells have been used in a number of studies where cell availability has been the limiting factor\[[@B21],[@B22]\]. However, no study has directly compared for instance biopsy and PBMC-derived responses in a systematic manner and on a single epitope level, and it is unclear whether the in vitro expansion provides identical data. In the present report, we have compared the response patterns to EBV- and HIV-derived antigens in directly ex vivo and in vitro expanded PBMC preparations. No significant differences were observed, although some responses are lost or gained upon expansion. As no difference in the concordance between EBV- and HIV-specific responses was observed, the data indicate that responses to both viruses are equally well expandable in vitro using an antigen-unspecific stimulus, despite the ongoing viral replication in most HIV infected subjects tested here.

Thus, optimal epitope matrices, RecycleSpot and in vitro expansion of cells can be combined to achieve maximal information on an extensive set of antigens, even if sample availability is limited. As a practical approach, expanded cells from frozen PBMC aliquots can be used initially to screen a large number of antigens to determine the approximate breadth of responses within the set of antigens used. Subsequent studies using unexpanded cells and antigen matrices in conjunction with RecycleSpot would then allow determination of the true breadth and, more importantly, the true magnitude of these responses while requiring minimal cell numbers. Furthermore, cells can be successfully recovered from the RecycleSpot once more to be used for genetic analyses such as HLA typing. This combined approach should facilitate future work in settings in which cell availability is of constant concern.

###### 

Optimal EBV-derived HLA class I restricted CTL epitopes

  Protein   HLA Restriction   Sequence          Position   Reference
  --------- ----------------- ----------------- ---------- -----------
  BMLF1     A1                LVSDYCNVLNKEFT    25--39     \[27\]
  BMLF1     A2                GLCTLVAML         280--288   \[28\]
  BMLF1     B18               DEVEFLGHY         397--405   \[28\]
  BMLF1     n.d.\*            KDTWLDARM         265--273   \[29\]
  BMLF1     A24               DYNFVKQLF         320--328   \[30\]
  BHRF      A2                LLWAARPRL         204--212   \[31\]
  BZLF1     B7                LPCVLWPVL         44--52     \[13\]
  BZLF1     B8                RAKFQLL           190--197   \[32\]
  BZLF1     Cw6               RKCCRAKFKQLLQH    186--201   \[1\]
  BMRF1     Cw6               YRSGIIAW          268--276   \[16\]
  BMRF1     Cw3               FRNLAYGRTCVLGK    86--100    \[16\]
  BRLF1     A2                YVLDHLIVV         109--117   \[33\]
  BRLF1     A2                RALIKTLPRASYSSH   225--239   \[27\]
  BRLF1     A3                RVRAYTYSK         148--156   \[1\]
  BRLF1     A11               ATIGTAMYK         134--142   \[16\]
  BRLF1     A24               DYCNVLNKEF        28--37     \[27\]
  BRLF1     A24               TYPVLEEMF         198--206   \[30\]
  BRLF1     B61               QKEEAAICGQMDLS    529--543   \[1\]
  BRLF1     Cw4               ERPIFPHPSKPTFLP   393--407   \[1\]
  gp110     A2                ILIYNGWYA         106--114   \[1\]
  gp110     B35               VPGSETMCY         544--552   \[1\]
  gp110     B35               APGWLIWTY         190--198   \[1\]
  gp85      A2                TLFIGSHVV         420--428   \[1\]
  gp85      A2                LMPIIPLINV        542--550   \[1\]
  gp85      A2                SLVIVTTFV         225--233   \[1\]
  gp350     A2                VLQWASLAV         863--871   \[1\]
  gp350     A2                VLTLLLLLV         871--879   \[34\]
  gp350     A2                LIPETVPYI         152--160   \[34\]
  gp350     A2                QLTPHTKAV         67--75     \[34\]
  EBNA1     A2                FMVFLQTHI         562--570   \[13\]
  EBNA1     B7                RPQKRPSCI         72--80     \[35\]
  EBNA1     B7                IPQCRLTPL         528--536   \[35\]
  EBNA1     B53               HPVGEADYF         407--415   \[35\]
  EBNA2     A2/B51            DTPLIPLTIF        42--50     \[36\]
  EBNA3A    A2                SVRDRLARL         596--604   \[37\]
  EBNA3A    A3                RLRAEAQVK         603--611   \[38\]
  EBNA3A    A24               RYSIFFDY          246--253   \[37\]
  EBNA3A    A29               VFSDGRVAC         491--499   \[16\]
  EBNA3A    A30               AYSSWMYSY         176--184   \[1\]
  EBNA3A    B7                RPPIFIRRL         379--387   \[39\]
  EBNA3A    B7                VPAPAGPIV         502--510   \[16\]
  EBNA3A    B8                QAKWRLQTL         158--166   \[37\]
  EBNA3A    B8                FLRGRAYGL         325--333   \[40\]
  EBNA3A    B35               YPLHEQYGM         458--466   \[37\]
  EBNA3A    B46               VQPPQLTLQV        617--625   \[41\]
  EBNA3A    B62               LEKARGSTY         406--414   \[16\]
  EBNA3A    n.d.\*            HLAAQGMAY         318--326   \[16\]
  EBNA3B    A1l               NPTQAPVIQLHAVY    101--115   \[40\]
  EBNA3B    A1l               AVFDRKSDAK        399--408   \[16\]
  EBNA3B    A1l               LPGPQVTAVLLHEES   481--495   \[40\]
  EBNA3B    A1l               DEPASTEPVHDQLL    551--563   \[40\]
  EBNA3B    Al1               IVTDFSVIK         416--424   \[40\]
  EBNA3B    A24               TYSAGIVQI         217--225   \[16\]
  EBNA3B    A27               RRARSLSAERY       243--253   \[42\]
  EBNA3B    B35               AVLLHEESM         488--496   \[1\]
  EBNA3B    B44               VEITPYKPTW        657--666   \[16\]
  EBNA3B    B58               VSFIEFVGW         279--287   \[43\]
  EBNA3B    B62               GQGGSPTAM         831--839   \[16\]
  EBNA3C    B7                QPRAPIRPI         881--889   \[39\]
  EBNA3C    B27               RRIYDLIEL         258--266   \[44\]
  EBNA3C    B27               HRCQAIRK          149--157   \[16\]
  EBNA3C    B27               FRKAQIQGL         343--351   \[16\]
  EBNA3C    B27               RKIYDLIEL         258--266   \[45\]
  EBNA3C    B27               RRIFDLIEL         258--266   \[45\]
  EBNA3C    B27               LRGKWQRRYR        249--258   \[44\]
  EBNA3C    B37               LDFVRFMGV         285--293   \[46\]
  EBNA3C    B39               HHIWQNLL          271--278   \[16\]
  EBNA3C    B44               KEHVIQNAF         335--343   \[47\]
  EBNA3C    B44               EENLLDFVRF        281--290   \[40\]
  EBNA3C    B44               EGGVGWRHW         163--171   \[48\]
  EBNA3C    B62               QNGALAINTF        213--222   \[49\]
  EBNALP    A2                SLREWLLRI         284--292   \[43\]
  LMP1      A2                YLQQNWWTL         159--167   \[50\]
  LMP1      A2                YLLEMLWRL         125--133   \[50\]
  LMP1      A2                LLVDLLWLL         167--175   \[50\]
  LMP1      A2                TLLVDLLWL         166--174   \[50\]
  LMP1      A2                LLLIALWNL         92--100    \[50\]
  LMP1      B51               DPHGPVQLSYYD      393--404   \[51\]
  LMP2      A2                FLYALALLL         356--364   \[52\]
  LMP2      A2                LLWTLWLL          329--337   \[53\]
  LMP2      A2                CLGGLLTMV         426--434   \[54\]
  LMP2      A2                LTAGFLIFL         453--461   \[53\]
  LMP2      A11               SSCSSCPLSKI       340--350   \[53\]
  LMP2      A23               PYLFWLAAI         131--139   \[55\]
  LMP2      A2                LLSAWILTA         447--455   \[43\]
  LMP2      A24               TYGPVFMCL         419--427   \[53\]
  LMP2      A24               IYVLVMLVL         222--230   \[30\]
  LMP2      A25               VMNSNTLLSAW       442--451   \[16\]
  LMP2      A27               RRRWRRLTV         236--244   \[44\]
  LMP2      B40               IEDPPFNSL         200--208   \[53\]
  LMP2      B63               WTLWLLI           331--338   \[1\]

\*not determined

###### 

Optimal CMV-derived HLA class I restricted CTL epitopes

  Protein   HLA Restriction   Sequence          Position   Reference
  --------- ----------------- ----------------- ---------- ------------
  pp65      B35               IPSINVHHY         123--131   \[56\]
  pp65      B35               DDVWTSGSDSDEELV   397--411   \[57\]
  pp65      B35               VFPTKDVAL         187--195   \[17\]
  pp65      B38               PTFTSQYRIQGKL     367--379   \[17\]
  pp65      B7                TPRVTGGGAM        417--426   \[57\]
  pp65      B7                RPHERNGFTVL       265--275   \[17\]
  pp65      A1                YSEHPTFTSQY       363--373   \[17\]
  pp65      A1101             SVLGPISGHVLK      13--24     \[17\]
  pp65      A2402             FTSQYRIQGKL       369--379   \[17\]
  pp65      A68               FVFPTKDVALP       186--196   \[17\]
  pp65      A2                NLVPMVATV         495--503   \[57\]
  pp65      A2                VLGPISGHV         14--22     \[58\]
  pp65      A2                MLNIPSINV         120--128   \[58\]
  pp65      B44               EFFWDANDIY        512--521   \[57\]
  pp65      A2402             VYALPLKML         113--121   \[59\]
  pp65      A2402/Cw0401      QYDPVAALF         341--349   \[60, 61\]
  pp65      B5201             QMWQARLTV         155--163   \[62\]
  pp65      A0207             RIFAELEGV         522--530   \[61\]
  pp65      A1101             ATVQGQNLK         501--509   \[61\]
  pp65      B1501             KMQVIGDQY         215--223   \[61\]
  pp65      B4001             CEDVPSGKL         232--240   \[61\]
  pp65      B40               HERNGFTVL         267--275   \[61\]
  pp65      B4006             AELEGVWQPA        525--534   \[61\]
  pp65      B4403             SEHPTFTSQY        364--373   \[61\]
  pp65      B5101             DALPGPCI          545--552   \[61\]
  pp65      Cw0102            RCPEMISVL         7--15      \[61\]
  pp65      Cw0801            VVCAHELVC         198--206   \[61\]
  pp65      Cw1202            VAFTSHEHF         294--302   \[61\]
  pp65      A33               SVNVHNPTGR        91--100    \[63\]
  pp150     A0301             TTVYPPSSTAK       945--955   \[17\]
  pp150     A68               QTVTSTPVQGR       792--802   \[17\]
  IE        B7                CRVLCCYVL         309--317   \[64\]
  IE        A2                YILEETSVM         315--323   \[65\]
  IE        B18               ELKRKMIYM         199--207   \[65\]
  IE        B18               CVETMCNEY         279--287   \[65\]
  IE        B18               DEEDAIVAY         379--387   \[65\]
  IE        B18               SDEEEAIVAYTL      378--389   \[56\]
  GB        A2                FIAGNSAYEYV       618--628   \[66\]

###### 

Optimal HCV-derived HLA class I restricted CTL epitopes

  Protein   HLA Restriction   Sequence      Position     Reference
  --------- ----------------- ------------- ------------ -----------
  Core      B60               GQIVGGVYLL    28--37       \[67\]
  Core      A0201             YLLPRRGPRL    35--44       \[68\]
  Core      B7                GPRLGVRAT     41--49       \[69\]
  Core      B44               NEGCGWAGW     88--96       \[70\]
  Core      A0201             DLMGYIPLV     132--140     \[71\]
  Core      A0201             ALAHGVRAL     150--158     \[15\]
  Core      A0201             LLALLSCLTV    178--187     \[72\]
  Core      A11               MSTNPKPQK     1--9         \[73\]
  P7        A29               FYGMWPLLL     790--798     \[15\]
  P7        Cw7               FYGMWPLL      790--797     \[15\]
  E1        A0201             ILHTPGCV      220--227     \[74\]
  E1        B35               NASRCWVAM     234--242     \[25\]
  E1        A0201             QLRRHIDLLV    257--266     \[74\]
  E1        A23               FLVGQLFTF     285--293     \[15\]
  E1        A0201             MMMNWSPTT     322--330     \[15\]
  E1        A0201             SMVGNWAKV     363--371     \[74\]
  E1        B35               CPNSSIVY      207--214     \[15\]
  E2        A0201             SLLAPGAKQNV   401--411     \[74\]
  E2        B53               CRPLTDFDQGW   460--469     \[69\]
  E2        B51               YPPKPCGI      489--496     \[73\]
  E2        B60               GENDTDVFVL    530--539     \[75\]
  E2        B50               CVIGGAGNNT    569--578     \[73\]
  E2        A0201             RLWHYPCTV     614--622     \[76\]
  E2        A11               TINYTIFK      621--628     \[69\]
  E2        B60               LEDRDRSEL     654--662     \[75\]
  E2        A2402             EYVLLLFLL     717--725     \[77\]
  E2        B57               NTRPPLGNWF    541--550     \[15\]
  NS2       A29               MALTLSPY      827--834     \[25\]
  NS2       A25               SPYYKRYISW    832--841     \[78\]
  NS2       A23               YISWCLWWL     838--845     \[69\]
  NS3       A24               AYSQQTRGL     1031--1039   \[79\]
  NS3       A0201             CINGVCWTV     1073--1081   \[68\]
  NS3       A0201             LLCPAGHAV     1169--1177   \[68\]
  NS3       A0201             LLCPSGHAV     1169--1177   \[68\]
  NS3       A11               TLGFGAYMSK    1261--1270   \[80\]
  NS3       A0201             ATLGFGAYM     1260--1268   \[81\]
  NS3       A0201             TLHGPTPLL     1617--1625   \[81\]
  NS3       A0201             TGAPVTYSTY    1287--1296   \[79\]
  NS3       A2402             TYSTYGKFL     1292--1300   \[77\]
  NS3       B35               HPNIEEVAL     1359--1367   \[82\]
  NS3       B8                HSKKKCDEL     1395--1403   \[69\]
  NS3       A0201             KLVALGINAV    1406--1415   \[68\]
  NS3       B8                LIRLKPTL      1611--1618   \[75\]
  NS3       A11               TLTHPVTK      1636--1643   \[80\]
  NS3       A68               HAVGLFRAA     1175--1184   \[15\]
  NS3       A0201             GLLGCIITSL    1038--1047   \[81\]
  NS4       A2402             FWAKHMWNF     1760--1768   \[77\]
  NS4       B35               IPDREVLY      1695--1712   \[15\]
  NS4       A24               VIAPAVQTNW    1745--1754   \[15\]
  NS4       B57               LTTSQTLLF     1801--1809   \[15\]
  NS4B      A25               EVIAPAVQTNW   1744--1754   \[78\]
  NS4B      A25               ETFWAKHMW     1758--1766   \[78\]
  NS4B      A0201             SLMAFTAAV     1789--1797   \[68\]
  NS4B      A0201             LLFNILGGWV    1807--1816   \[72\]
  NS4B      A0201             ILAGYGAGV     1851--1859   \[72\]
  NS4B      B37               SECTTPCSGSW   1966--1976   \[78\]
  NS4B      B38               AARVTAIL      1941--1948   \[75\]
  NS5       A2                VLSDFKTWL     1987--1995   \[83\]
  NS5       B35               EPEPDVAVL     2162--2170   \[15\]
  NS5       B57               LGVPPLRAWR    2912--2921   \[15\]
  NS5A      B60               HEYPVGSQL     2152--2160   \[75\]
  NS5A      B35               PCEPEPDVAVL   2161--2171   \[75\]
  NS5A      B38               NHDSPDAEL     2218--2226   \[75\]
  NS5A      A2                SPDAELIEANL   2221--2231   \[75\]
  NS5A      A25               ELIEANLLW     2225--2233   \[78\]
  NS5A      A0201             ILDSFDPLV     2252--2260   \[68\]
  NS5A      B60               REISVPAEIL    2267--2275   \[80\]
  NS5B      A3                SLTPPHSAK     2510--2518   \[80\]
  NS5B      A3                RVCEKMALY     2588--2596   \[69\]
  NS5B      A2                ALYDWTKL      2594--2602   \[78\]
  NS5B      B57               KSKKTPMGF     2629--2637   \[80\]
  NS5B      A0201             GLQDCTMLV     2727--2735   \[72\]
  NS5B      B38               HDGAGKRVYL    2794--2804   \[80\]
  NS5B      A25               TARHTPVNSW    2819--2828   \[78\]
  NS5B      A2402             RMILMTHFF     2841--2849   \[77\]
  NS5B      A2402             CYSIEPLDL     2870--2878   \[77\]
  NS5B      A31               VGIYLLPNR     3003--3011   \[80\]
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